+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Multiple Myeloma Market Size, Share & Industry Trends Analysis Report By End User, By Disease Type (Active Multiple Myeloma and Smoldering Multiple Myeloma), By Drug Type, By Country and Growth Forecast, 2023-2029

  • PDF Icon

    Report

  • 99 Pages
  • April 2023
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5806473
The Latin America, Middle East and Africa Multiple Myeloma Market should witness market growth of 16.5% CAGR during the forecast period (2023-2029).

The growth of nanomedicine platforms, the increasing usage of microRNA therapies, and the ongoing development of efficient and secure medications all contribute to developing the multiple myeloma market. The medication sector is projected to grow when histone deacetylase (HDAC) inhibitors and monoclonal antibodies are added to the current treatment options. Clinicians choose biological therapy using monoclonal antibodies like darzalex and empliciti because of the documented clinical profile.

As the disease's symptoms start manifesting as active myeloma, doctors determine whether to use the second and third lines of therapy. Stem cell transplant operations are typically included in the first line. The method entails storing bone marrow and stem cells outside the patient's body, followed by a strong dosage of chemotherapy or radiation and bone marrow replenishment and stem cells. There is a high demand for allogeneic stem cell transplants rather than autologous ones, the two main forms of stem cell transplants.

In Latin America, many treatment methods of MM have been tested. The disease had little effect from chemotherapy combined with dexamethasone, but developing new medications like protease inhibitors or IMiDs significantly improved the prospects for MM patients. Thalidomide was the first medication to demonstrate success, and it was already available in numerous Latin American nations, including Brazil, as it is inexpensive and thus accessible in this region. MM therapy combines this medication with dexamethasone or dexamethasone and alkylating drugs. The rising prevalence of multiple myeloma and the availability of treatment drugs are propelling the advancement of the regional market.

The Brazil market dominated the LAMEA Multiple Myeloma Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $772.4 Million by 2029. The Argentina market is exhibiting a CAGR of 17.1% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 16.2% during (2023-2029).

Based on End-user, the market is segmented into Hospitals, Clinics, and Others. Based on Disease Type, the market is segmented into Active Multiple Myeloma and Smoldering Multiple Myeloma. Based on Drug Type, the market is segmented into Protease Inhibitors, Monoclonal Antibody, Chemotherapy and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.

Scope of the Study

By End-user

  • Hospitals
  • Clinics
  • Others

By Disease Type

  • Active Multiple Myeloma
  • Smoldering Multiple Myeloma

By Drug Type

  • Protease Inhibitors
  • Monoclonal Antibody
  • Chemotherapy
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Novartis AG
  • Bristol Myers Squibb Company
  • Amgen, Inc.
  • AbbVie, Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Baxter International, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Pfizer, Inc.

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Multiple Myeloma Market, by End User
1.4.2 LAMEA Multiple Myeloma Market, by Disease Type
1.4.3 LAMEA Multiple Myeloma Market, by Drug Type
1.4.4 LAMEA Multiple Myeloma Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 Analyst's Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)

Chapter 4. LAMEA Multiple Myeloma Market by End User
4.1 LAMEA Hospitals Market by Country
4.2 LAMEA Clinics Market by Country
4.3 LAMEA Others Market by Country

Chapter 5. LAMEA Multiple Myeloma Market by Disease Type
5.1 LAMEA Active Multiple Myeloma Market by Country
5.2 LAMEA Smoldering Multiple Myeloma Market by Country

Chapter 6. LAMEA Multiple Myeloma Market by Drug Type
6.1 LAMEA Protease Inhibitors Market by Country
6.2 LAMEA Monoclonal Antibody Market by Country
6.3 LAMEA Chemotherapy Market by Country
6.4 LAMEA Others Market by Country

Chapter 7. LAMEA Multiple Myeloma Market by Country
7.1 Brazil Multiple Myeloma Market
7.1.1 Brazil Multiple Myeloma Market by End User
7.1.2 Brazil Multiple Myeloma Market by Disease Type
7.1.3 Brazil Multiple Myeloma Market by Drug Type
7.2 Argentina Multiple Myeloma Market
7.2.1 Argentina Multiple Myeloma Market by End User
7.2.2 Argentina Multiple Myeloma Market by Disease Type
7.2.3 Argentina Multiple Myeloma Market by Drug Type
7.3 UAE Multiple Myeloma Market
7.3.1 UAE Multiple Myeloma Market by End User
7.3.2 UAE Multiple Myeloma Market by Disease Type
7.3.3 UAE Multiple Myeloma Market by Drug Type
7.4 Saudi Arabia Multiple Myeloma Market
7.4.1 Saudi Arabia Multiple Myeloma Market by End User
7.4.2 Saudi Arabia Multiple Myeloma Market by Disease Type
7.4.3 Saudi Arabia Multiple Myeloma Market by Drug Type
7.5 South Africa Multiple Myeloma Market
7.5.1 South Africa Multiple Myeloma Market by End User
7.5.2 South Africa Multiple Myeloma Market by Disease Type
7.5.3 South Africa Multiple Myeloma Market by Drug Type
7.6 Nigeria Multiple Myeloma Market
7.6.1 Nigeria Multiple Myeloma Market by End User
7.6.2 Nigeria Multiple Myeloma Market by Disease Type
7.6.3 Nigeria Multiple Myeloma Market by Drug Type
7.7 Rest of LAMEA Multiple Myeloma Market
7.7.1 Rest of LAMEA Multiple Myeloma Market by End User
7.7.2 Rest of LAMEA Multiple Myeloma Market by Disease Type
7.7.3 Rest of LAMEA Multiple Myeloma Market by Drug Type

Chapter 8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental &Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Trials and Approvals:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Product Launches and Product Expansions:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Trials and Approvals:
8.4 Amgen, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.4.5.2 Acquisition and Mergers:
8.5 AbbVie, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Baxter International, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.7 Teva Pharmaceutical Industries Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Product Launches and Product Expansions:
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Trials and Approvals:
8.9.5.2 Acquisition and Mergers:
8.10. Takeda Pharmaceutical Company Limited
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense

Companies Mentioned

  • Novartis AG
  • Bristol Myers Squibb Company
  • Amgen, Inc.
  • AbbVie, Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Baxter International, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Pfizer, Inc.

Methodology

Loading
LOADING...